Answer
Women of childbearing potential and men with female partners of reproductive potential must use effective contraception during ripretinib (QINLOCK) treatment and for at least one week after the final dose.
Sources for this answer
- QINLOCK 50 mg tabletsDeciphera · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked